Pradusinstobart

普拉苏拜单抗

Report date: 2023/03/16 16:28:33

Base Information

Drug NamePradusinstobart
Drug Alias NameLVGN-3616SSI-361
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLyvgen Biopharma(HK)Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLyvgen Biopharma(HK)LtdUniversity Of PennsylvaniaAnhui Anke Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A